Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
<Research>Nomura Raises JD HEALTH's TP to HKD80 w/ Higher Earnings Forecasts
Recommend 3 Positive 9 Negative 3 |
||||
|
||||
|
According to Nomura's research report, JD HEALTH (06618.HK)'s 3Q25 results were exceptional, with total revenue, driven by YoY increases of 30%/ 30%/ around 15% in pharmaceutical/ nutritional product/ medical device sales, growing by 29% YoY to RMB17 billion, 4% higher than the broker's estimate. Nomura raised its FY25-26 earnings forecasts for JD HEALTH by 9% and 8%, respectively. JD HEALTH's rating was kept as Buy, with a target price lifted from HKD72 to HKD80. AAStocks Financial News |
||||
Copied to Clipboard
 |
||||
